Investors

Key press releases

27 Sep 2023
16:30 E.S.T.

Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

07 Aug 2023
09:41 E.S.T.

Cellectis Provides Full Report for Second Quarter 2023 Financial Results

03 Aug 2023
12:52 E.S.T.

Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023

Key upcoming events

24 Oct 2023 ‐ 27 Oct 2023

European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Conference

Learn more

Key corporate presentation

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on the Euronext Growth Paris (ticker: ALCLS).

$1.5800

0.0000 (0.0000%)

Prev. close: 1.5800
Volume: 7,365
High: 1.5900
Capitalization: 72.168M

€1.4760

+0.0120 (0.8197%)

Prev. close: 1.4640
Volume: 7,721
High: 1.4760
Capitalization: 82.042M

See stock information

Covering research analysts

Barclays - Gena Wang

Bryan Garnier - Alex Cogut

Citi - Yigal Nochomovitz

Goldman Sachs - Salveen Richter

Jefferies - Kelly Shi

JMP Securities - Silvan Tuerkcan

Jones Trading - Soumit Roy

Kempen - Sebastiaan van der Schoot

Oddo BHF - Martial Descoutures

Oppenheimer – Hartaj Singh

RW Baird - Jack Allen

Wells Fargo – Yanan Zhu

Cellectis contact information

Arthur Stril, Chief Business Officer

Ashley R. Robinson, LifeSci Advisors

investors@cellectis.com

Citibank ADR contact information

Intermediaries & Investors
US: +1 212 723 5435
UK: +44 207 500 2030

citiadr@citi.com

Société Générale Securities Services - Ordinary Shares contact information

Call center in English and French

Monday to Friday from 8:30am to 6pm CEST

+33 (0)2 51 85 67 89